Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0145)
Name
Ropivacaine
Synonyms
Ropivacaine; 84057-95-4; (S)-Ropivacaine; Naropin; Ropivacaine [INN]; Ropivacaine hydrochloride; Ropivacaina; Ropivacainum; Ropivacaina [Spanish]; S-Ropivacaine; (S)-N-(2,6-Dimethylphenyl)-1-propylpiperidine-2-carboxamide; Ropivacainum [INN-Latin]; Ropivacaina [INN-Spanish]; (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide; Ropivicaine; Ropivacaine base; (2S)-N-(2,6-dimethylphenyl)-1-propyl-piperidine-2-carboxamide; 7IO5LYA57N; (-)-1-Propyl-2',6'-pipecoloxylidide; LEA 103; CHEBI:8890; TLC590; (2S)-N-(2,6-dimethylphenyl)-1-propyl-2-piperidinecarboxamide; TLC-590; Ropivacaine (INN); MFCD00864425; L-N-n-propylpipecolic acid-2,6-xylidide; 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (2S)-; (S)-(-)-1-propyl-2',6'-pipecoloxylidide; 1-propyl-2',6'-pipecoloxylidide; Noropine; Narop; LEA-103 HCl; Naropin (TN); LEA-103; NCGC00164597-01; Ropivacaine [INN:BAN]; UNII-7IO5LYA57N; AL-381; ROPIVACAINE [MI]; ROPIVACAINE [VANDF]; SCHEMBL33292; ROPIVACAINE [USP-RS]; ROPIVACAINE [WHO-DD]; BIDD:GT0203; Narop; Noropine; LEA-103; GTPL7602; (-)-1-Propyl-2',6'-dimethyl-2-piperidylcarboxyanilid; CHEMBL1077896; DTXSID4040187; ZKMNUMMKYBVTFN-HNNXBMFYSA-N; HY-B0563; BBL102321; s5504; STL556120; AKOS017343283; CCG-267197; DB00296; AS-35173; CS-0009514; R0251; C07532; D08490; AB00698466-07; AB00698466_10; EN300-7436767; A840710; Q279504; (S)-(-)-1-PROPYL-2',6'-PIPECOLOXYLIDINE; Q-201677; (-)-1-propyl-2',6'-dimethyl-2-piperidylcarboxyanilide; Z2235811359; (s)-n-(2,6-dimethylphenyl)-1-propyl-2-piperidinecarboxamide; (S)-(-)-1-PROPYLPIPERIDINE-2-CARBOXYLIC ACID (2,6-DIMETHYLPHENYL)AMIDE

    Click to Show/Hide
Status
Approved
Drug Type
Small molecular drug
Structure
Formula
C17H26N2O
IUPAC Name
(2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide
Canonical SMILES
CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C
InChI
InChI=1S/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20)/t15-/m0/s1
InChIKey
ZKMNUMMKYBVTFN-HNNXBMFYSA-N
PubChem CID
175805
TTD Drug ID
D09RHQ
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 2 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Ovarian cancer ICD-11: 2C73
 Disease Info 
Responsed Regulator Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) Suppressor
 Regulator Info 
Pathway Response PI3K-Akt signaling pathway hsa04151
Fatty acid metabolism hsa01212
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model SK-OV-3 cells Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
OVCAR-3 cells Ovarian serous adenocarcinoma Homo sapiens CVCL_0465
In Vivo Model
Twelve Nude female BALB/c-nu mice (5-weeks-old) were from Shanghai Lab. Animal Research Center (Shanghai, China). SKOV3 cells (5 x 106) were injected subcutaneously into mice according to the previously described methods with minor changes. To evaluate the effect of ropivacaine on the growth of ovarian cancer, ropivacaine (10 mg/kg) was injected intraperitoneally into mice referring to the previously reported methods with minor revisions. The size of the tumor was measured every day and the tumor volumes were calculated by the formula: length x width2/2 = tumor volume (mm3). When the tumor size reached 2000 mm3, all mice were sacrificed and the excised tumor tissues were weighed to evaluate the antitumor effect.

    Click to Show/Hide
Response regulation The mechanism results confirmed that ropivacaine inactivated the PI3K/AKT signaling pathway in ovarian cancer cells. Furthermore, in vivo assay demonstrated that ropivacaine repressed the proliferation of ovarian cancer cells in vivo and had a protective function in ovarian cancer.
Experiment 2 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Ovarian cancer ICD-11: 2C73
 Disease Info 
Responsed Regulator RAC-alpha serine/threonine-protein kinase (AKT1) Suppressor
 Regulator Info 
Pathway Response PI3K-Akt signaling pathway hsa04151
Fatty acid metabolism hsa01212
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model SK-OV-3 cells Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
OVCAR-3 cells Ovarian serous adenocarcinoma Homo sapiens CVCL_0465
In Vivo Model
Twelve Nude female BALB/c-nu mice (5-weeks-old) were from Shanghai Lab. Animal Research Center (Shanghai, China). SKOV3 cells (5 x 106) were injected subcutaneously into mice according to the previously described methods with minor changes. To evaluate the effect of ropivacaine on the growth of ovarian cancer, ropivacaine (10 mg/kg) was injected intraperitoneally into mice referring to the previously reported methods with minor revisions. The size of the tumor was measured every day and the tumor volumes were calculated by the formula: length x width2/2 = tumor volume (mm3). When the tumor size reached 2000 mm3, all mice were sacrificed and the excised tumor tissues were weighed to evaluate the antitumor effect.

    Click to Show/Hide
Response regulation The mechanism results confirmed that ropivacaine inactivated the PI3K/AKT signaling pathway in ovarian cancer cells. Furthermore, in vivo assay demonstrated that ropivacaine repressed the proliferation of ovarian cancer cells in vivo and had a protective function in ovarian cancer.
References
Ref 1 Ropivacaine represses the ovarian cancer cell stemness and facilitates cell ferroptosis through inactivating the PI3K/AKT signaling pathway. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221120652. doi: 10.1177/09603271221120652.